Anteris Receives German Regulatory Clearance for PARADIGM Trial Expansion
Anteris Technologies Global said it received full regulatory clearance from Germany’s BfArM for expansion of its PARADIGM trial.
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for th…